Percutaneous ultrasound-guided cyst sclerotherapy in patients with polycystic liver disease

Authors:

Abstract
Background: Polycystic liver disease (PCLD) is a genetic disease causing hepatomegaly and local cystic complications. To date, there is no established medical therapy for PCLD. We present our results of percutaneous minimal-invasive cyst sclerotherapy in patients with PCLD. Patients and methods: 301 pat. with PCLD were followed by our centre between 2001 – 2008 and retrospectively analysed. Mean age was 50 ± 11 years with 19% male. Additional polycystic kidney disease was found in 63% of pat. All pat. received a special questionnaire to report their subjective follow-up. Follow-up was 33 ± 27 months. 31 pat. underwent liver transplantation during this period. A total of 31 pat. died during follow-up, 9 of them with liver-associated cause of death. Cyst sclerotherapy was performed in pat. with a minimum cyst size of 8 – 10 cm or with symptomatic cysts. For sclerotherapy, cyst fluid was aspired with a 20G needle under ultrasound-guidance. Around 10% of the aspired volume was then administered into the cyst in form of 1% ethoxysclerol. In cysts with a diameter of > 15 cm, cyst drainage was performed to empty them first and perform sclerotherapy via drainage thereafter. In infected or sanguinous cysts, they were rinsed with NaCl 0,9% instead of sclerotherapy. Results: A total of 422 cyst therapy sessions of 903 cysts with a mean diameter of 8,1 ± 3,7 cm was performed in 149 pat. (50%). This included 705 sclerotherapies, 33 drainages and 110 cyst rinsing therapies. Indications for cyst therapy were especially symptomatic cysts (67%) and cyst size (48%). The questionnaire of 150 pat. could be analysed, 85 of them underwent cyst therapies leading to a subjective improvement of symptoms in 88% of them. Complications of cyst therapy were noted in 26% of cases, mostly local pain (16%) or inflammatory signs (16%). Bleedings occurred in < 1%. Conclusions: Percutaneous ultrasound-guided cyst sclerotherapy is easy, effective, cheap and with few complications to improve symptoms of patients with PCLD.